Leadership

Leadership has overseen repeated capital raises and dilution, which has reduced per-share value creation versus better-disciplined small-cap biotech peers.

The company’s negative return on equity and limited operating leverage indicate management has not translated strategic decisions into durable shareholder returns.

Decision-making appears reactive rather than consistently execution-focused, with outcomes lagging peers that have maintained tighter cost control and clearer development milestones.

Execution

Execution has not produced sustained profitability, as negative ROE suggests management’s operating plans have failed to convert spending into efficient returns.

The absence of visible multi-year share count discipline points to weaker execution versus peers that have better preserved ownership through financing choices.

Management’s outcomes imply inconsistent delivery against long-term value targets, especially relative to peers that have shown steadier milestone execution and capital efficiency.

Capital Allocation

Capital allocation has been poor, with dilution and repeated financing needs indicating management has prioritized survival funding over per-share value creation.

A net debt to EBITDA ratio near 0.9 alongside zero reported debt-to-equity does not offset the broader pattern of weak capital discipline versus peers.

Management has not demonstrated the restraint seen at stronger peers, where financing decisions are more selective and less destructive to existing shareholders.

Incentives

Incentive alignment appears weak because persistent dilution and poor returns suggest management outcomes have not been tightly tied to per-share value creation.

Compared with peers that emphasize ownership preservation and milestone-based accountability, MYNZ’s results imply less effective alignment between pay, decisions, and shareholder outcomes.

The pattern of negative returns and financing dependence suggests incentives have not sufficiently reinforced disciplined execution or capital stewardship.

Overall Score

Management quality is weak because repeated dilution, poor returns, and limited capital discipline have outweighed any evidence of consistent execution.

Score Driver: Persistent Shareholder Dilution With Weak Per-Share Value Creation